Stephen M. Bloch net worth and biography

Stephen Bloch Biography and Net Worth

Director of Liquidia

Dr. Block has helped start and finance leading healthcare companies as a General Partner at Canaan Partners for more than 23 years. In addition to Canaan, he is currently CEO of EvolveImmune Therapeutics, a leader in next generation immune-oncology therapeutics and CEO of Allyx Therapeutics, whose lead program will enter phase 2 testing in Alzheimer’s and Parkinson’s patients in 2025. Steve was BioCT’s Entrepreneur of the Year in 2023. Steve has served on the boards of companies in biopharma, digital health, medical devices and diagnostics, often as board chairman. Before joining Canaan in 2002, Steve helped create and manage multiple start-ups, including RMS, one of the first radiology benefits companies where he was CEO for six years. Previously, Steve was a strategic pharmaceutical consultant for Arthur D. Little and an Ewing Marion Kauffman Fellow. Steve is currently a member of Dartmouth-Geisel Medical School’s Board of Advisors. Steve obtained his AB from Dartmouth College, a MA in the history of science from Harvard, and his medical degree from the University of Rochester. Steve completed his residency at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine).

What is Stephen M. Bloch's net worth?: The estimated net worth of Stephen M. Bloch is at least $82.39 million as of March 27th, 2026. Dr. Bloch owns 2,188,935 shares of Liquidia stock worth more than $82,393,702 as of April 8th. This net worth approximation does not reflect any other investments that Dr. Bloch may own. Learn More about Stephen M. Bloch's net worth.
How do I contact Stephen M. Bloch?: The corporate mailing address for Dr. Bloch and other Liquidia executives is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. Liquidia can also be reached via phone at (919) 328-4400 and via email at [email protected]. Learn More on Stephen M. Bloch's contact information.
Has Stephen M. Bloch been buying or selling shares of Liquidia?: Stephen M. Bloch has not been actively trading shares of Liquidia during the past quarter. Most recently, Stephen M. Bloch sold 62,550 shares of the business's stock in a transaction on Friday, March 27th. The shares were sold at an average price of $35.94, for a transaction totalling $2,248,047.00. Following the completion of the sale, the director now directly owns 2,188,935 shares of the company's stock, valued at $78,670,323.90. Learn More on Stephen M. Bloch's trading history.
Who are Liquidia's active insiders?: Liquidia's insider roster includes Jason Adair (Chief Business Officer), Stephen Bloch (Director), Dana Boyle (CAO), Roger Jeffs (CEO), Michael Kaseta (CFO), Arthur Kirsch (Director), Sarah Krepp (Insider), Paul Manning (Director), Scott Moomaw (Chief Commercial Officer), Rajeev Saggar (Insider), Russell Schundler (General Counsel), and Raman Singh (Director). Learn More on Liquidia's active insiders.
Are insiders buying or selling shares of Liquidia?: In the last year, insiders at the sold shares 58 times. They sold a total of 1,377,277 shares worth more than $39,527,084.54. The most recent insider tranaction occured on March, 27th when Director Stephen M Bloch sold 62,550 shares worth more than $2,248,047.00. Insiders at Liquidia own 30.1% of the company. Learn More about insider trades at Liquidia.
Information on this page was last updated on 3/27/2026.

Stephen M. Bloch Insider Trading History at Liquidia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/27/2026	Sell	62,550	$35.94	$2,248,047.00	2,188,935

Stephen M. Bloch Buying and Selling Activity at Liquidia

Liquidia Company Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Today's Range

Now: $38.19

$37.57

$38.97

50 Day Range

MA: $37.19

$30.00

$46.63

2 Week Range

Now: $38.19

$11.26

$46.67

Volume

948,951 shs

Average Volume

1,819,884 shs

Market Capitalization

$3.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45